Naoko Hidaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naoko Hidaka has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Hajime Kato
Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo 113-8655
13 shared publications - Nobuaki Ito
Division of Therapeutic Development for Intractable Bone Diseases, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo 113-0033 , Tokyo
13 shared publications - Masaomi Nangaku
Division of Nephrology and Endocrinology, Graduate School of Medicine The University of Tokyo Tokyo Japan
11 shared publications - Noriko Makita
Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo 113-8655
10 shared publications - Yoshitomo Hoshino
Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo 113-8655
9 shared publications Minae Koga
Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo 113-8655
8 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (11)
Involvement of reduced ENPP1 function in the pathogenesis of ossification of the posterior longitudinal ligament
Ossification of the posterior longitudinal ligament (OPLL) is an ectopic ossification disorder with incompletely understood pathophysiology. In a previously reported 50-patient OPLL cohort, ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) exonic heterozygous variants were identified in 7 patients (14%), and plasma inorganic pyrophosphate (PPi), a biochemical marker reflecting ENPP1 function, was lower in patients with OPLL than in cervical osteoarthritis controls regardless of ENPP1 variant status. However, the clinical significance of ENPP1 variants and reduced PPi in OPLL, as well as the possible presence of non-genetic ENPP1 dysfunction, remains unclear. The study included the same cohort of 50 patients with OPLL as in our previous study, 7 of whom had ENPP1 variants. Clinical, biochemical, and radiographic characteristics were compared according to ENPP1 variant status and cohort median PPi level. Anti-ENPP1 autoantibodies were evaluated in an exploratory analysis using a luciferase immunoprecipitation system (LIPS) assay in 29 patients with available serum samples. Patients with ENPP1 variants showed higher serum FGF23 levels than those without variants (median 46 vs 36 pg/mL, p = .011) and tended to have lower plasma PPi levels (1477 vs 1693 nM, p = .052), suggesting partial impairment of ENPP1 function. However, radiographic ossification indices, diffuse idiopathic skeletal hyperostosis (DISH), and surgical characteristics did not differ by variant status. In contrast, DISH was more frequent in the lower-PPi group than in the higher-PPi group (72% vs 44%, p = .045). No apparent anti-ENPP1 autoantibodies were detected using the LIPS assay. Ectonucleotide pyrophosphatase/phosphodiesterase 1 exonic heterozygous variants may contribute to OPLL through partial ENPP1 dysfunction. More broadly, reduced ENPP1 function itself, regardless of variant status, may be involved in ectopic ligament ossification in OPLL, although anti-ENPP1 autoantibodies were not detected in the current study. The broader involvement of ENPP1 dysfunction in OPLL may indicate a wider population that could potentially benefit from future ENPP1 replacement therapy.
- 17 September 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (11)
Open AccessInvolvement of reduced ENPP1 function in the pathogenesis of ossification of the posterior longitudinal ligament
Ossification of the posterior longitudinal ligament (OPLL) is an ectopic ossification disorder with incompletely understood pathophysiology. In a previously reported 50-patient OPLL cohort, ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) exonic heterozygous variants were identified in 7 patients (14%), and plasma inorganic pyrophosphate (PPi), a biochemical marker reflecting ENPP1 function, was lower in patients with OPLL than in cervical osteoarthritis controls regardless of ENPP1 variant status. However, the clinical significance of ENPP1 variants and reduced PPi in OPLL, as well as the possible presence of non-genetic ENPP1 dysfunction, remains unclear. The study included the same cohort of 50 patients with OPLL as in our previous study, 7 of whom had ENPP1 variants. Clinical, biochemical, and radiographic characteristics were compared according to ENPP1 variant status and cohort median PPi level. Anti-ENPP1 autoantibodies were evaluated in an exploratory analysis using a luciferase immunoprecipitation system (LIPS) assay in 29 patients with available serum samples. Patients with ENPP1 variants showed higher serum FGF23 levels than those without variants (median 46 vs 36 pg/mL, p = .011) and tended to have lower plasma PPi levels (1477 vs 1693 nM, p = .052), suggesting partial impairment of ENPP1 function. However, radiographic ossification indices, diffuse idiopathic skeletal hyperostosis (DISH), and surgical characteristics did not differ by variant status. In contrast, DISH was more frequent in the lower-PPi group than in the higher-PPi group (72% vs 44%, p = .045). No apparent anti-ENPP1 autoantibodies were detected using the LIPS assay. Ectonucleotide pyrophosphatase/phosphodiesterase 1 exonic heterozygous variants may contribute to OPLL through partial ENPP1 dysfunction. More broadly, reduced ENPP1 function itself, regardless of variant status, may be involved in ectopic ligament ossification in OPLL, although anti-ENPP1 autoantibodies were not detected in the current study. The broader involvement of ENPP1 dysfunction in OPLL may indicate a wider population that could potentially benefit from future ENPP1 replacement therapy.
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (10) , ziag140
Impact of burosumab on kinetics of intact FGF23 values after the removal of a causative tumor in a patient with tumor-induced osteomalacia
Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome caused by tumors secreting fibroblast growth factor 23 (FGF23). Burosumab, an anti-FGF23 antibody, is used for the management of TIO. However, burosumab therapy significantly elevates serum intact FGF23 levels, rendering preoperative systemic venous sampling unreliable. This report aims to evaluate the half-life of measured intact FGF23 in a TIO patient treated with burosumab and to elucidate its effect on the kinetics of intact FGF23 levels. A 13-yr-old female who had been receiving burosumab for TIO underwent wide excision of an FGF23-positive phosphaturic mesenchymal tumor located in the right distal femur. Burosumab was discontinued postoperatively, and intact FGF23 levels were measured sequentially at outpatient follow-ups. The half-life was calculated using a single-phase exponential decay model based on postoperative days and measured intact FGF23 levels. Although hypophosphatemia resolved following tumor removal, measured intact FGF23 levels remained high (44 300 pg/mL on postoperative day 1) but gradually declined and normalized (29.5 pg/mL on postoperative day 271). Based on these measurements, the half-life of measured intact FGF23 was calculated to be 20.2 d. This half-life is similar to that of burosumab itself, likely reflecting the presence of biologically inactive FGF23–burosumab complexes. In conclusion, the half-life of measured intact FGF23 following burosumab discontinuation is considerably longer than that reported in TIO patients not receiving burosumab, indicating that measured intact FGF23 levels should be interpreted with caution after discontinuation of burosumab.
- 20 August 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (10) , ziag140
Open AccessImpact of burosumab on kinetics of intact FGF23 values after the removal of a causative tumor in a patient with tumor-induced osteomalacia
Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome caused by tumors secreting fibroblast growth factor 23 (FGF23). Burosumab, an anti-FGF23 antibody, is used for the management of TIO. However, burosumab therapy significantly elevates serum intact FGF23 levels, rendering preoperative systemic venous sampling unreliable. This report aims to evaluate the half-life of measured intact FGF23 in a TIO patient treated with burosumab and to elucidate its effect on the kinetics of intact FGF23 levels. A 13-yr-old female who had been receiving burosumab for TIO underwent wide excision of an FGF23-positive phosphaturic mesenchymal tumor located in the right distal femur. Burosumab was discontinued postoperatively, and intact FGF23 levels were measured sequentially at outpatient follow-ups. The half-life was calculated using a single-phase exponential decay model based on postoperative days and measured intact FGF23 levels. Although hypophosphatemia resolved following tumor removal, measured intact FGF23 levels remained high (44 300 pg/mL on postoperative day 1) but gradually declined and normalized (29.5 pg/mL on postoperative day 271). Based on these measurements, the half-life of measured intact FGF23 was calculated to be 20.2 d. This half-life is similar to that of burosumab itself, likely reflecting the presence of biologically inactive FGF23–burosumab complexes. In conclusion, the half-life of measured intact FGF23 following burosumab discontinuation is considerably longer than that reported in TIO patients not receiving burosumab, indicating that measured intact FGF23 levels should be interpreted with caution after discontinuation of burosumab.
- 13 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e1-e8
PHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing
Context: Loss-of-function variants in the PHEX gene cause X-linked hypophosphatemia (XLH) with inappropriate secretion of fibroblast growth factor 23. The PHEX protein is therefore predicted to be involved in the phosphate (Pi)-sensing mechanism in mature osteocytes. The parathyroid glands sense short-term fluctuations in serum Pi levels and secrete PTH accordingly. However, the precise mechanisms for Pi sensing in the parathyroid gland have not been elucidated. Objective: To clarify the involvement of PHEX in phosphate sensing in the parathyroid glands, PTH reactions after Pi loading were retrospectively compared between patients with XLH and those with tumor-induced osteomalacia (TIO). Methods: Serum Pi, intact PTH (iPTH) and albumin-corrected serum calcium (cCa) levels at 1 hour after oral phosphate administration at doses ranging from 300 to 1500 mg were analyzed. The trend of iPTH in each participant was compared between XLH and TIO. Results: Six XLH patients and 13 TIO patients were included. The serum Pi level significantly increased after the oral Pi load, whereas the serum cCa level was stable. The slope of the scatter plot of iPTH (pg/mL) vs Pi (mg/dL) after the oral Pi load for each patient was 41.4 (median) in XLH, which was significantly greater than the 7.1 in TIO (P = .034). Conclusion: iPTH increased in accordance with Pi levels, with a greater slope observed in XLH than in TIO after oral Pi loading. This finding suggests that PHEX in the parathyroid glands might also determine the serum Pi-sensing threshold and mediate PTH secretion in the case of abrupt fluctuations in serum Pi levels, which may explain the high prevalence of secondary and tertiary hyperparathyroidism in patients with XLH.
- 13 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e1-e8
PHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing
Context: Loss-of-function variants in the PHEX gene cause X-linked hypophosphatemia (XLH) with inappropriate secretion of fibroblast growth factor 23. The PHEX protein is therefore predicted to be involved in the phosphate (Pi)-sensing mechanism in mature osteocytes. The parathyroid glands sense short-term fluctuations in serum Pi levels and secrete PTH accordingly. However, the precise mechanisms for Pi sensing in the parathyroid gland have not been elucidated. Objective: To clarify the involvement of PHEX in phosphate sensing in the parathyroid glands, PTH reactions after Pi loading were retrospectively compared between patients with XLH and those with tumor-induced osteomalacia (TIO). Methods: Serum Pi, intact PTH (iPTH) and albumin-corrected serum calcium (cCa) levels at 1 hour after oral phosphate administration at doses ranging from 300 to 1500 mg were analyzed. The trend of iPTH in each participant was compared between XLH and TIO. Results: Six XLH patients and 13 TIO patients were included. The serum Pi level significantly increased after the oral Pi load, whereas the serum cCa level was stable. The slope of the scatter plot of iPTH (pg/mL) vs Pi (mg/dL) after the oral Pi load for each patient was 41.4 (median) in XLH, which was significantly greater than the 7.1 in TIO (P = .034). Conclusion: iPTH increased in accordance with Pi levels, with a greater slope observed in XLH than in TIO after oral Pi loading. This finding suggests that PHEX in the parathyroid glands might also determine the serum Pi-sensing threshold and mediate PTH secretion in the case of abrupt fluctuations in serum Pi levels, which may explain the high prevalence of secondary and tertiary hyperparathyroidism in patients with XLH.
- Open Access
- 16 January 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziaf010
Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone
Excess fibroblast growth factor 23 (FGF23), a mature osteocyte-derived phosphaturic hormone, causes chronic hypophosphatemic osteomalacia in adults. This rare condition was recently reported in 2 alcoholic patients, with marked improvement upon cessation of alcohol consumption, suggesting a link between alcohol and FGF23-related hypophosphatemia within the highly limited cases. This study aimed to investigate whether the source of excess FGF23 in alcohol-induced FGF23-related hypophosphatemic osteomalacia is the bone or the other organs. To achieve this goal, an immunohistochemical approach for the bone obtained from a patient was employed. Initial attempts at quantifying FGF23 in the bone using conventional immunohistochemistry (IHC) faced issues in quantifiability and sensitivity for low FGF23 expression levels. Therefore, next-generation IHC with phosphor-integrated dots (PIDs) was applied, which enabled the quantification of FGF23 expression in the bone across a broad range. Preliminary analyses using IHC with PIDs on normal bone samples (n = 12) provided a reference level (154.5 PID particles per cell). IHC with PIDs quantified suppressed physiological FGF23 expression in the bone samples from 3 patients with tumor-induced osteomalacia, where FGF23 is oversecreted from a tumor (13.6 PID particles per cell). Subsequently, bone samples obtained from a 70-yr-old male with alcohol-induced FGF23-related hypophosphatemic osteomalacia were analyzed, showing a higher number of PID particles per cell (199.4 PID particles per cell) than the reference level. This study suggests that orthotopic, bone-derived FGF23 is implicated in alcohol-induced FGF23-related hypophosphatemic osteomalacia. Furthermore, the study also demonstrated that highly sensitive IHC with PIDs could aid in the differential diagnosis of FGF23-related hypophosphatemia of unknown origin. Specifically, a bone sample with a low number of PID particles per cell indicates an excess ectopic secretion of FGF23; a bone sample with a normal to high number of PID particles per cell indicates an excess orthotopic secretion of FGF23.
- 16 January 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziaf010
Open AccessExcess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone
Excess fibroblast growth factor 23 (FGF23), a mature osteocyte-derived phosphaturic hormone, causes chronic hypophosphatemic osteomalacia in adults. This rare condition was recently reported in 2 alcoholic patients, with marked improvement upon cessation of alcohol consumption, suggesting a link between alcohol and FGF23-related hypophosphatemia within the highly limited cases. This study aimed to investigate whether the source of excess FGF23 in alcohol-induced FGF23-related hypophosphatemic osteomalacia is the bone or the other organs. To achieve this goal, an immunohistochemical approach for the bone obtained from a patient was employed. Initial attempts at quantifying FGF23 in the bone using conventional immunohistochemistry (IHC) faced issues in quantifiability and sensitivity for low FGF23 expression levels. Therefore, next-generation IHC with phosphor-integrated dots (PIDs) was applied, which enabled the quantification of FGF23 expression in the bone across a broad range. Preliminary analyses using IHC with PIDs on normal bone samples (n = 12) provided a reference level (154.5 PID particles per cell). IHC with PIDs quantified suppressed physiological FGF23 expression in the bone samples from 3 patients with tumor-induced osteomalacia, where FGF23 is oversecreted from a tumor (13.6 PID particles per cell). Subsequently, bone samples obtained from a 70-yr-old male with alcohol-induced FGF23-related hypophosphatemic osteomalacia were analyzed, showing a higher number of PID particles per cell (199.4 PID particles per cell) than the reference level. This study suggests that orthotopic, bone-derived FGF23 is implicated in alcohol-induced FGF23-related hypophosphatemic osteomalacia. Furthermore, the study also demonstrated that highly sensitive IHC with PIDs could aid in the differential diagnosis of FGF23-related hypophosphatemia of unknown origin. Specifically, a bone sample with a low number of PID particles per cell indicates an excess ectopic secretion of FGF23; a bone sample with a normal to high number of PID particles per cell indicates an excess orthotopic secretion of FGF23.
- Open Access
- 22 October 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (12) , bvae184
Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia
Context Causative factors for ectopic ossifications in X-linked hypophosphatemia (XLH) remain to be elucidated. Objective To investigate the genotype-phenotype correlations between PHEX and ectopic ossifications in XLH. Methods Biochemical data, spinal computed tomography scans, and X-rays of hip/knee joints were retrospectively reviewed. Genetic analysis and the measurement of plasma inorganic pyrophosphate (PPi) - a potent inhibitor of tissue calcification - were performed. The effect of PHEX mutations on protein function was predicted using nonsense-mediated decay (NMD) and 3D structure modeling. The index of ossification of the anterior/posterior longitudinal ligament and yellow ligament (OA/OP/OY index) and the sum of the OA/OP/OY index (OS index) were used to quantify the severity of spinal ligament ossification. The severity of the hip/knee osteoarthritis was evaluated by the Kellgren-Lawrence classification. Results We examined 24 distinct pathogenic PHEX variants in 28 patients from a study population of 33 individuals in 27 unrelated, non-consanguineous families. Among the 31 patients whose plasma samples were analyzed for PPi, 14 patients (45%) showed decreased plasma PPi concentrations, however, PPi concentrations did not correlate with mutation type or ectopic ossification. Fibroblast growth factor 23 levels in females with NMD-insensitive mutations trended lower than in males with NMD-sensitive mutations but failed to reach statistical significance. Both models revealed no correlations between PHEX pathogenic variant and ectopic ossification. Conclusion Neither modeling found correlates between PHEX pathogenic variants and ectopic ossificatio. The effects of PPi on ectopic ossifications in adults with XLH revealed trends that should be investigated with a large sample size.
- 22 October 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (12) , bvae184
Open AccessEffect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia
Context Causative factors for ectopic ossifications in X-linked hypophosphatemia (XLH) remain to be elucidated. Objective To investigate the genotype-phenotype correlations between PHEX and ectopic ossifications in XLH. Methods Biochemical data, spinal computed tomography scans, and X-rays of hip/knee joints were retrospectively reviewed. Genetic analysis and the measurement of plasma inorganic pyrophosphate (PPi) - a potent inhibitor of tissue calcification - were performed. The effect of PHEX mutations on protein function was predicted using nonsense-mediated decay (NMD) and 3D structure modeling. The index of ossification of the anterior/posterior longitudinal ligament and yellow ligament (OA/OP/OY index) and the sum of the OA/OP/OY index (OS index) were used to quantify the severity of spinal ligament ossification. The severity of the hip/knee osteoarthritis was evaluated by the Kellgren-Lawrence classification. Results We examined 24 distinct pathogenic PHEX variants in 28 patients from a study population of 33 individuals in 27 unrelated, non-consanguineous families. Among the 31 patients whose plasma samples were analyzed for PPi, 14 patients (45%) showed decreased plasma PPi concentrations, however, PPi concentrations did not correlate with mutation type or ectopic ossification. Fibroblast growth factor 23 levels in females with NMD-insensitive mutations trended lower than in males with NMD-sensitive mutations but failed to reach statistical significance. Both models revealed no correlations between PHEX pathogenic variant and ectopic ossification. Conclusion Neither modeling found correlates between PHEX pathogenic variants and ectopic ossificatio. The effects of PPi on ectopic ossifications in adults with XLH revealed trends that should be investigated with a large sample size.
- Open Access
- 20 November 2023
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 7 (12) , e10842
The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult‐Onset Hypophosphatasia
Hypophosphatasia (HPP) is an inherited disease caused by variants of the ALPL gene encoding tissue‐nonspecific alkaline phosphatase. Adult‐onset HPP (adult HPP), known as a mild form of HPP, develops symptoms involving osteomalacia after the age of 18 years. Asfotase alfa (AA) is a modulated recombinant human alkaline phosphatase (ALP) that has been established as a first‐line therapy for severe forms of HPP, such as perinatal and infantile forms. We described a 64‐year‐old female who presented with pseudofractures in bilateral femur diaphyses and impaired mobility. Low serum ALP activity and a high concentration of urine phosphoethanolamine indicated the diagnosis of HPP, which was confirmed by the identification of a homozygous variant in the ALPL gene (c.319G > A; p.Val107Ile). An in vitro transfection experiment to measure the ALP activity of this novel variant protein was performed, resulting in 40% of the residual enzymatic activity compared with the wild type. AA was initiated to facilitate the union of pseudofracture and to improve mobility. After 6 months, radiographic images revealed the disappearance of fracture lines, and improvement of ambulatory ability was confirmed by the 6‐minute walk test (525 to 606 m). The EQ‐5D‐5L index was also improved (0.757 to 0.895). Within a follow‐up period, the levels of urine pyrophosphate corrected by urine creatinine (uPPi/Cre) declined in parallel with the level of plasma PPi (plasma PPi: 6.34 to 1.04 μM, uPPi/Cre: 226.8 to 75.4 nmol/mg). The beneficial effect of AA on pseudofracture healing in adult HPP was presented, although the application of AA should be restricted to patients exhibiting relatively severe manifestations. In addition, a novel pathogenic variant of the ALPL gene was identified with the supportive result of functional analysis. Furthermore, when monitoring patients with HPP treated with AA, uPPi/Cre might be a convenient substitute for plasma PPi, which requires immediate filtration after blood sampling. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
- 20 November 2023
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 7 (12) , e10842
Open AccessThe Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult‐Onset Hypophosphatasia
Hypophosphatasia (HPP) is an inherited disease caused by variants of the ALPL gene encoding tissue‐nonspecific alkaline phosphatase. Adult‐onset HPP (adult HPP), known as a mild form of HPP, develops symptoms involving osteomalacia after the age of 18 years. Asfotase alfa (AA) is a modulated recombinant human alkaline phosphatase (ALP) that has been established as a first‐line therapy for severe forms of HPP, such as perinatal and infantile forms. We described a 64‐year‐old female who presented with pseudofractures in bilateral femur diaphyses and impaired mobility. Low serum ALP activity and a high concentration of urine phosphoethanolamine indicated the diagnosis of HPP, which was confirmed by the identification of a homozygous variant in the ALPL gene (c.319G > A; p.Val107Ile). An in vitro transfection experiment to measure the ALP activity of this novel variant protein was performed, resulting in 40% of the residual enzymatic activity compared with the wild type. AA was initiated to facilitate the union of pseudofracture and to improve mobility. After 6 months, radiographic images revealed the disappearance of fracture lines, and improvement of ambulatory ability was confirmed by the 6‐minute walk test (525 to 606 m). The EQ‐5D‐5L index was also improved (0.757 to 0.895). Within a follow‐up period, the levels of urine pyrophosphate corrected by urine creatinine (uPPi/Cre) declined in parallel with the level of plasma PPi (plasma PPi: 6.34 to 1.04 μM, uPPi/Cre: 226.8 to 75.4 nmol/mg). The beneficial effect of AA on pseudofracture healing in adult HPP was presented, although the application of AA should be restricted to patients exhibiting relatively severe manifestations. In addition, a novel pathogenic variant of the ALPL gene was identified with the supportive result of functional analysis. Furthermore, when monitoring patients with HPP treated with AA, uPPi/Cre might be a convenient substitute for plasma PPi, which requires immediate filtration after blood sampling. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
- Open Access
- 2 February 2023
- Published by Elsevier in Bone Reports
- Vol. 18, 101659
Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
- 2 February 2023
- Published by Elsevier in Bone Reports
- Vol. 18, 101659
Open AccessClinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
- 16 December 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (6) , 1405-1414
Effect of Conventional Treatment on Dental Complications and Ectopic Ossifications Among 30 Adults With XLH
Context: Conventional treatment of X-linked hypophosphatemia (XLH) was reported to prevent dental complications, but whether the preventive effect was different among different types of teeth, including anterior teeth and molar teeth, is uncertain. Evidence of the preventive effect of conventional treatment on ectopic ossifications is also limited. Objective: To compare dental complications and ectopic ossifications among adults with XLH with early (<5 years old) or late (≥5 years old) conventional treatment. Methods: This retrospective observational study included a total of 30 adults with XLH; orthopantomograms, spinal computed tomography scans, and X-rays of hip/knee joints were studied. Dental complications, including the decayed, missing, filled (DMF) index and devitalized teeth, apical periodontitis, and periodontitis, were evaluated. The ossification of the anterior/posterior longitudinal ligament and yellow ligament indexes (OA/OP/OY indexes) and the sum of the OA/OP/OY indexes (OS index) were utilized to evaluate the severity of spinal ligament ossification. The severity of the hip/knee osteophytes was evaluated using the Kellgren–Lawrence (KL) classification. Results: The number of sound teeth was significantly lower and the DMF index was significantly higher in patients with late treatment. The severity of dental complications in the anterior tooth and molar tooth, OA/OP/OY/OS index, and KL grade were not significantly different among patients with early treatment and those with late treatment. Conclusion: Early treatment could prevent dental complications but did not prevent ectopic ossification in adult patients with XLH. The difference in the preventive effect was not observed among different types of teeth.
- 16 December 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (6) , 1405-1414
Effect of Conventional Treatment on Dental Complications and Ectopic Ossifications Among 30 Adults With XLH
Context: Conventional treatment of X-linked hypophosphatemia (XLH) was reported to prevent dental complications, but whether the preventive effect was different among different types of teeth, including anterior teeth and molar teeth, is uncertain. Evidence of the preventive effect of conventional treatment on ectopic ossifications is also limited. Objective: To compare dental complications and ectopic ossifications among adults with XLH with early (<5 years old) or late (≥5 years old) conventional treatment. Methods: This retrospective observational study included a total of 30 adults with XLH; orthopantomograms, spinal computed tomography scans, and X-rays of hip/knee joints were studied. Dental complications, including the decayed, missing, filled (DMF) index and devitalized teeth, apical periodontitis, and periodontitis, were evaluated. The ossification of the anterior/posterior longitudinal ligament and yellow ligament indexes (OA/OP/OY indexes) and the sum of the OA/OP/OY indexes (OS index) were utilized to evaluate the severity of spinal ligament ossification. The severity of the hip/knee osteophytes was evaluated using the Kellgren–Lawrence (KL) classification. Results: The number of sound teeth was significantly lower and the DMF index was significantly higher in patients with late treatment. The severity of dental complications in the anterior tooth and molar tooth, OA/OP/OY/OS index, and KL grade were not significantly different among patients with early treatment and those with late treatment. Conclusion: Early treatment could prevent dental complications but did not prevent ectopic ossification in adult patients with XLH. The difference in the preventive effect was not observed among different types of teeth.
- Open Access
- 24 November 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (2) , bvac181
Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors
Context Tumor-induced osteomalacia (TIO) is one of the most common forms of acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemia and is usually caused by phosphaturic mesenchymal tumors (PMTs). Although the complete resection of PMTs can cure TIO, preoperative localization of tumors by standard imaging modalities is often challenging. In addition to 18F-fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography (FDG-PET) and 111In-pentetreotide scintigraphy (SRS), systemic FGF23 venous sampling (FGF23VS) has been used to help localize PMTs in specialized institutions. Objective This study aimed to evaluate the diagnostic performance of each imaging test and their combinations in localizing PMTs. Methods In an observational retrospective study of patients with adult-onset FGF23-related osteomalacia who underwent all 3 imaging studies (FDG-PET, SRS, and FGF23VS), the rate of successful preoperative localization of the tumors was evaluated only in the patients with pathological diagnoses of PMTs, considering the possibility that pathogenesis of patients without identified tumors might be due to other causes such as late-onset hereditary FGF23-related hypophosphatemia. Results A total of 30 Japanese patients with TIO (median age, 60 years [range, 28-87 years]; 10 women [33.3%]) were included in the study. The success rate of preoperative localization for each test and combinations of 2 or 3 tests among 18 patients with PMTs was as follows: 72% (FDG-PET), 72% (SRS), 94% (FGF23VS), 89% (FDG-PET, SRS), 100% (FDG-PET, FGF23VS), 94% (SRS, FGF23VS), and 100% (FDG-PET, SRS, and FGF23VS). Conclusion We observed the highest localization rate of PMTs in patients with identified PMTs with the combination of FDG-PET and FGF23VS.
- 24 November 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (2) , bvac181
Open AccessUtility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors
Context Tumor-induced osteomalacia (TIO) is one of the most common forms of acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemia and is usually caused by phosphaturic mesenchymal tumors (PMTs). Although the complete resection of PMTs can cure TIO, preoperative localization of tumors by standard imaging modalities is often challenging. In addition to 18F-fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography (FDG-PET) and 111In-pentetreotide scintigraphy (SRS), systemic FGF23 venous sampling (FGF23VS) has been used to help localize PMTs in specialized institutions. Objective This study aimed to evaluate the diagnostic performance of each imaging test and their combinations in localizing PMTs. Methods In an observational retrospective study of patients with adult-onset FGF23-related osteomalacia who underwent all 3 imaging studies (FDG-PET, SRS, and FGF23VS), the rate of successful preoperative localization of the tumors was evaluated only in the patients with pathological diagnoses of PMTs, considering the possibility that pathogenesis of patients without identified tumors might be due to other causes such as late-onset hereditary FGF23-related hypophosphatemia. Results A total of 30 Japanese patients with TIO (median age, 60 years [range, 28-87 years]; 10 women [33.3%]) were included in the study. The success rate of preoperative localization for each test and combinations of 2 or 3 tests among 18 patients with PMTs was as follows: 72% (FDG-PET), 72% (SRS), 94% (FGF23VS), 89% (FDG-PET, SRS), 100% (FDG-PET, FGF23VS), 94% (SRS, FGF23VS), and 100% (FDG-PET, SRS, and FGF23VS). Conclusion We observed the highest localization rate of PMTs in patients with identified PMTs with the combination of FDG-PET and FGF23VS.
- 11 April 2022
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (6) , 1125-1135
Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis
Homozygous ENPP1 mutations are associated with autosomal recessive hypophosphatemic rickets type 2 (ARHR2), severe ossification of the spinal ligaments, and generalized arterial calcification of infancy type 1. There are a limited number of reports on phenotypes associated with heterozygous ENPP1 mutations. Here, we report a series of three probands and their families with heterozygous and compound heterozygous ENPP1 mutations. The first case (case 1) was a 47-year-old male, diagnosed with early-onset osteoporosis and low-normal serum phosphate levels, which invoked suspicion for hypophosphatemic rickets. The second and third cases were 77- and 54-year-old females who both presented with severe spinal ligament ossification and the presumptive diagnosis of diffuse idiopathic skeletal hyperostosis (DISH). Upon workup, fibroblast growth factor 23 (FGF23) was noted to be relatively high in case 2 and serum phosphorous was low-normal in case 3, and the diagnoses of X-linked hypophosphatemic rickets (XLH) and ARHR2 were considered. Genetic testing for genes related to congenital hypophosphatemic rickets was therefore performed, revealing heterozygous ENPP1 variants in cases 1 and 2 (case 1, c.536A>G, p.Asn179Ser; case 2, c.1352A>G, p.Tyr451Cys) and compound heterozygous ENPP1 variants in case 3 constituting the same variants present in cases 1 and 2 (c.536A>G, p.Asn179Ser and c.1352A>G, p.Tyr451Cys). Several in silico tools predicted the two variants to be pathogeneic, a finding confirmed by in vitro biochemical analysis demonstrating that the p.Asn179Ser and p.Tyr451Cys ENPP1 variants possessed a catalytic velocity of 45% and 30% compared with that of wild-type ENPP1, respectively. Both variants were therefore categorized as pathogenic loss-of-function mutations. Our findings suggest that ENPP1 mutational status should be evaluated in patients presenting with the diagnosis of idiopathic DISH, ossification of the posterior longitudinal ligament (OPLL), and early-onset osteoporosis. © 2022 American Society for Bone and Mineral Research (ASBMR).
- 11 April 2022
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (6) , 1125-1135
Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis
Homozygous ENPP1 mutations are associated with autosomal recessive hypophosphatemic rickets type 2 (ARHR2), severe ossification of the spinal ligaments, and generalized arterial calcification of infancy type 1. There are a limited number of reports on phenotypes associated with heterozygous ENPP1 mutations. Here, we report a series of three probands and their families with heterozygous and compound heterozygous ENPP1 mutations. The first case (case 1) was a 47-year-old male, diagnosed with early-onset osteoporosis and low-normal serum phosphate levels, which invoked suspicion for hypophosphatemic rickets. The second and third cases were 77- and 54-year-old females who both presented with severe spinal ligament ossification and the presumptive diagnosis of diffuse idiopathic skeletal hyperostosis (DISH). Upon workup, fibroblast growth factor 23 (FGF23) was noted to be relatively high in case 2 and serum phosphorous was low-normal in case 3, and the diagnoses of X-linked hypophosphatemic rickets (XLH) and ARHR2 were considered. Genetic testing for genes related to congenital hypophosphatemic rickets was therefore performed, revealing heterozygous ENPP1 variants in cases 1 and 2 (case 1, c.536A>G, p.Asn179Ser; case 2, c.1352A>G, p.Tyr451Cys) and compound heterozygous ENPP1 variants in case 3 constituting the same variants present in cases 1 and 2 (c.536A>G, p.Asn179Ser and c.1352A>G, p.Tyr451Cys). Several in silico tools predicted the two variants to be pathogeneic, a finding confirmed by in vitro biochemical analysis demonstrating that the p.Asn179Ser and p.Tyr451Cys ENPP1 variants possessed a catalytic velocity of 45% and 30% compared with that of wild-type ENPP1, respectively. Both variants were therefore categorized as pathogenic loss-of-function mutations. Our findings suggest that ENPP1 mutational status should be evaluated in patients presenting with the diagnosis of idiopathic DISH, ossification of the posterior longitudinal ligament (OPLL), and early-onset osteoporosis. © 2022 American Society for Bone and Mineral Research (ASBMR).